In spondyloarthritides (SpA) and fibromyalgia (FM), patients suffer from generalized pain. The impact of FM on PRO validated in SpA has not been systematically studied. Study the performance of PROs developed for SpA in patients with primary (p) FM without chronic inflammatory-rheumatic disease vs. SpA without and with concomitant (c) FM. Patients with pFM, axSpA or PsA and indication for treatment adaptation were prospectively included. Standardized PROs were assessed: BASDAI, ASDAS-CRP, DAPSA, patient´s global assessment, BASFI, LEI, MASES, SPARCC Enthesitis Score and FIQ. 300 patients were included (100/diagnosis). More males were found in axSpA vs. PsA and pFM group (67, 33 and 2/100, respectively), while 12 axSpA (axSpA+) and 16 PsA (PsA+) patients had cFM. pFM patients showed significantly higher scores in all assessments vs. axSpA or PsA, with exception of ASDAS-CRP (3.3 ± 0.6 in FM vs. 3.1 ± 1.0 in axSpA) and duration of low lumbar morning stiffness. Similar results were also found in the subanalysis of female patients only. In addition, patients with axSpA + or PsA + showed no differences to patients with pFM, while significantly higher scores were found for FM, axSpA + and PsA + for almost all FIQ items compared to axSpA- or PsA-. PROs originally developed for axSpA or PsA need to be interpreted differently in the presence or absence of cFM. ASDAS-CRP and duration of lumbar morning stiffness were not affected by cFM. FM-specific questionnaires also showed high scores in patients with SpA with cFM but not in those without.

中文翻译：

---

针对原发性纤维肌痛和伴随形式的纤维肌痛中的脊柱关节炎制定的标准化患者报告结果的表现


脊柱关节炎 (SpA) 和纤维肌痛 (FM) 患者会遭受全身疼痛。 FM 对 SpA 中验证的 PRO 的影响尚未得到系统研究。研究针对 SpA 开发的 PRO 在不伴有慢性炎症-风湿病的原发性 (p) FM 患者与不伴有或伴有 (c) FM 的 SpA 患者中的表现。前瞻性纳入 pFM、axSpA 或 PsA 以及适应治疗指征的患者。评估标准化 PRO：BASDAI、ASDAS-CRP、DAPSA、患者整体评估、BASFI、LEI、MASES、SPARCC 附着点炎评分和 FIQ。纳入 300 名患者（100 名/诊断）。与 PsA 和 pFM 组相比，axSpA 组中男性较多（分别为 67、33 和 2/100），而 12 名 axSpA (axSpA+) 和 16 名 PsA (PsA+) 患者患有 cFM。 pFM 患者在所有评估中均表现出明显高于 axSpA 或 PsA 的得分，但 ASDAS-CRP 除外（FM 为 3.3 ± 0.6，axSpA 为 3.1 ± 1.0）和低腰椎晨僵持续时间。在仅对女性患者进行的亚分析中也发现了类似的结果。此外，axSpA + 或 PsA + 患者与 pFM 患者没有差异，而与 axSpA- 或 PsA- 相比，几乎所有 FIQ 项目的 FM、axSpA + 和 PsA + 得分均显着更高。最初为 axSpA 或 PsA 开发的 PRO 在存在或不存在 cFM 的情况下需要进行不同的解释。 ASDAS-CRP 和腰椎晨僵持续时间不受 cFM 影响。 FM 特异性问卷也显示，患有 cFM 的 SpA 患者得分较高，但没有 cFM 的 SpA 患者得分则较低。